---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-21-004081"
form_type: "8-K"
ticker: "LONA"
cik: "0001620463"
company_name: "LeonaBio, Inc."
filed_at: "2021-11-10T23:59:59+00:00"
generated_at: "2026-06-28T09:58:07.572636+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Athira Pharma Q3 net loss $15.7M; ACT-AD trial enrollment completed

## Summary
- Net loss of $15.7M ($0.42 per share) vs $8.5M loss in Q3 2020; R&D spend $10.7M.
- Cash, cash equivalents and investments $339.4M as of Sept 30, 2021, up from $268.2M at Dec 31, 2020.
- Completed enrollment in Phase 2 ACT-AD trial (77 subjects); topline data expected H1 2022.
- LIFT-AD Phase 2/3 actively recruiting; topline data expected by end of 2022.
- SHAPE Phase 2 trial (Parkinson's dementia) anticipated to initiate by end of 2021; IND for ATH-1020 expected by end of 2021.

## SEC filing metadata
- accession: 0000950170-21-004081
- form_type: 8-K
- ticker: LONA
- cik: 0001620463
- company_name: LeonaBio, Inc.
- filed_at: 2021-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1620463/000095017021004081/0000950170-21-004081-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1620463/000095017021004081/atha-20211110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-21-004081
- JSON: https://secwatch.observer/filing/0000950170-21-004081.json
- Plain text: https://secwatch.observer/filing/0000950170-21-004081.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.